Department of Neurology and Institute of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Fujian Key Laboratory of Molecular Neurology, Fuzhou, China.
Eur J Neurol. 2018 Feb;25(2):356-364. doi: 10.1111/ene.13509. Epub 2017 Dec 21.
Facial-sparing scapular myopathy (SHD) is the most common atypical form of facioscapulohumeral muscular dystrophy (FSHD), clinically defined as without apparent facial muscle weakness on neurological examination. The clinical profiles and genetic features of SHD are limited.
A cohort of 21 Chinese patients with SHD were confirmed by molecular genetic analysis based on pulsed-field gel electrophoresis. The clinical assessments and methylation analysis were noted.
The patients had FSHD-related EcoRI fragments with 4qA haplotype ranging from 18 kb to 33 kb (mean 26.3 ± 4.6 kb). The mean onset age was 25.52 ± 8.3 years. Over half of the patients had scapular winging and asymmetry weakness consistent with FSHD, without facial symptoms during their visit. Their facial electromyogram results were almost normal or mild myogenic damage, as well as the myopathology and serum creatine kinase. A conflict was unexpectedly found in intergenerational DR1 methylation analysis.
Facial-sparing scapular myopathy is characterized as mild myopathic symptoms and chronic progression of weakness. The diagnosis should be accurately confirmed through FSHD-sized fragment detection and 4qA/B variant determination. Although the next generations of SHD had more severe muscular symptoms, local hypomethylation within D4Z4 was not found as a modifier for clinical heterogeneity.
面肩肱型肌营养不良症(SHD)是面肩肱型肌营养不良症(FSHD)中最常见的非典型形式,临床上定义为神经系统检查无明显面部肌无力。SHD 的临床特征和遗传特征有限。
对 21 例经分子遗传学分析基于脉冲场凝胶电泳证实的中国 SHD 患者进行临床评估和甲基化分析。
患者均具有 4qA 单体型的 FSHD 相关 EcoRI 片段,大小为 18kb 至 33kb(平均 26.3 ± 4.6kb)。平均发病年龄为 25.52 ± 8.3 岁。超过一半的患者有肩胛带翼状和不对称性无力,与 FSHD 一致,但就诊时无面部症状。他们的面部肌电图结果几乎正常或轻度肌源性损害,以及肌病和血清肌酸激酶。在代际 DR1 甲基化分析中发现了一个意外的冲突。
面肩肱型肌营养不良症的特征是轻度肌病症状和进行性无力。诊断应通过 FSHD 大小片段检测和 4qA/B 变体确定准确确认。尽管 SHD 的下一代患者有更严重的肌肉症状,但未发现 D4Z4 内局部低甲基化是临床异质性的修饰因子。